Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

[1] Association AD(2016)Standards of medical care in diabetes Diabetes Care 39 S1-112

[2] Bays HE(2016)National lipid association annual summary of clinical lipidology 2016 J Clin Lipidol 10 S1-43

[3] Jones PH(2015)National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report J Clin Lipidol 9 129-169

[4] Orringer CE(2011)Diabetes mellitus, fasting glucose, and risk of cause-specific death N Engl J Med 364 829-841

[5] Brown WV(2015)Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the american diabetes association and the European association for the study of diabetes Diabetes Care 38 140-149

[6] Jacobson TA(2011)Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes Endocr Rev 32 515-531

[7] Jacobson TA(2016)Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism Diabetes 65 2032-2038

[8] Ito MK(2018)The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus Intern Med 57 2147-2156

[9] Maki KC(2017)Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels J Clin Lipidol 11 450-458.e451

[10] Orringer CE(2021)Cardiovascular, renal, and metabolic outcomes of dapagliflozin versus placebo in a primary cardiovascular prevention cohort: analyses from DECLARE-TIMI 58 Diabetes Care 44 1159-1167

[1] Association AD(2016)Standards of medical care in diabetes Diabetes Care 39 S1-112

[2] Bays HE(2016)National lipid association annual summary of clinical lipidology 2016 J Clin Lipidol 10 S1-43

[3] Jones PH(2015)National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report J Clin Lipidol 9 129-169

[4] Orringer CE(2011)Diabetes mellitus, fasting glucose, and risk of cause-specific death N Engl J Med 364 829-841

[5] Brown WV(2015)Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the american diabetes association and the European association for the study of diabetes Diabetes Care 38 140-149

[6] Jacobson TA(2011)Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes Endocr Rev 32 515-531

[7] Jacobson TA(2016)Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism Diabetes 65 2032-2038

[8] Ito MK(2018)The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus Intern Med 57 2147-2156

[9] Maki KC(2017)Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels J Clin Lipidol 11 450-458.e451

[10] Orringer CE(2021)Cardiovascular, renal, and metabolic outcomes of dapagliflozin versus placebo in a primary cardiovascular prevention cohort: analyses from DECLARE-TIMI 58 Diabetes Care 44 1159-1167